Common biological pathways underlying the psychoneurological symptom cluster in cancer patients

Cancer Nursing

Volumn 35, Issue 6, 2012, Pages

  Kim, Hee Ju ^a   Barsevick, Andrea M ^b   Fang, Carolyn Y ^b   Miaskowski, Christine ^c  

^a Seoul Metropolitan Government Seobuk Hospital   (South Korea)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biological mechanism; Cancer; Sickness behavior; Symptom cluster; Symptom management

Indexed keywords

ACETYLCHOLINE; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ESTROGEN; INTERLEUKIN 6; METHYLPHENIDATE; MONOAMINE; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; PEMOLINE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ANHEDONIA; ANOREXIA; ANXIETY; ARTICLE; BEHAVIOR; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CIRCADIAN RHYTHM; COGNITIVE DEFECT; COUGHING; DECREASED APPETITE; DEPRESSION; DROWSINESS; DYSPHAGIA; DYSPNEA; EMOTIONAL STRESS; ESTROGEN BLOOD LEVEL; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HOARSENESS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILLNESS BEHAVIOR; MEMORY DISORDER; MENTAL DISEASE; MOOD; MOUTH PAIN; NAUSEA; NEUROLOGIC DISEASE; NEUROTRANSMISSION; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SLEEP DISORDER; SORE THROAT; TASTE DISORDER; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

CLUSTER ANALYSIS; COGNITION DISORDERS; COMORBIDITY; CRITICAL PATHWAYS; DEPRESSIVE DISORDER; EVIDENCE-BASED MEDICINE; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; NEOPLASMS; PAIN, INTRACTABLE; PREVALENCE; PROGNOSIS; PSYCHOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SURVIVAL RATE; SYNDROME;

EID: 84868304280     PISSN: 0162220X     EISSN: 15389804     Source Type: Journal    
DOI: 10.1097/NCC.0b013e318233a811     Document Type: Article

References (246)

1. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001; 28(3):465-470.
2. Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: Concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28(4):270-282; quiz 274-283.
3. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004; 11(5):279-292.
4. Miaskowski C, Aouizerat BE. Is there a biological basis for the clustering of symptoms? Semin Oncol Nurs. 2007;23(2):99-105.
5. Beck SL, Dudley WN, Barsevick A. Pain, sleep disturbance, and fatigue in patients with cancer: Using a mediation model to test a symptom cluster. Oncol Nurs Forum. 2005;32(3):542.
6. Given B, Given C, Azzouz F, Stommel M. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res. 2001;50(4):222-232.
7. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743-753.
8. Gaston-Johansson F, Fall-Dickson JM, Bakos AB, Kennedy MJ. Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Pract. 1999;7(5):240-247.
9. Given CW, Given B, Azzouz F, Kozachik S, Stommel M. Predictors of pain and fatigue in the year following diagnosis among elderly cancer patients. J Pain Symptom Manage. 2001;21(6):456-466.
10. Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH. Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. J Pain Symptom Manage. 1999; 18(4):233-242.
11. Bender CM, Ergyn FS, Rosenzweig MQ, Cohen SM, Sereika SM. Symptom clusters in breast cancer across 3 phases of the disease. Cancer Nurs. 2005;28(3):219-225.
12. Kim HJ, Barsevick AM, Tulman L, McDermott PA. Treatment-related symptom clusters in breast cancer: A secondary analysis. J Pain Symptom Manage. 2008;36(5):468-479.
13. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634-1646.
14. Gift AG, Jablonski A, Stommel M, Given CW. Symptom clusters in elderly patients with lung cancer. Oncol Nurs Forum. 2004;31(2): 202-212.
15. Chen ML, Tseng HC. Symptom clusters in cancer patients. Support Care Cancer. 2006;14(8):825-830.
16. Walsh D, Rybicki L. Symptom clustering in advanced cancer. Support Care Cancer. 2006;14(8):831-836.
17. Gleason JF Jr, Case D, Rapp SR, et al. Symptom clusters in patients with newly-diagnosed brain tumors. J Support Oncol. 2007;5(9):427-433, 436.
18. Fan G, Hadi S, Chow E. Symptom clusters in patients with advancedstage cancer referred for palliative radiation therapy in an outpatient setting. Support Cancer Ther. 2007;4(3):157-162.
19. Chow E, Fan G, Hadi S, Wong J, Kirou-Mauro A, Filipczak L. Symptom clusters in cancer patients with brain metastases. Clin Oncol (R Coll Radiol). 2008;20(1):76-82.
20. Wang SY, Tsai CM, Chen BC, Lin CH, Lin CC. Symptom clusters and relationships to symptom interference with daily life in Taiwanese lung cancer patients. J Pain Symptom Manage. 2008;35(3):258-266.
21. Cheung WY, Le LW, Zimmermann C. Symptom clusters in patients with advanced cancers. Support Care Cancer. 2009;17(9):1223-1230.
22. Kim E, Jahan T, Aouizerat BE, et al. Changes in symptom clusters in patients undergoing radiation therapy. Support Care Cancer. 2009;17(11): 1383-1391.
23. Hird A, Wong J, Zhang L, et al. Exploration of symptoms clusters within cancer patients with brain metastases using the Spitzer Quality of Life Index. Support Care Cancer. 2010;18(3):335-342.
24. Kirkova J, Aktas A, Walsh D, Rybicki L, Davis MP. Consistency of symptom clusters in advanced cancer. Am J Hosp Palliat Care. 2010;27(5): 342-346.
25. Molassiotis A, Wengstrom Y, Kearney N. Symptom cluster patterns during the first year after diagnosis with cancer. J Pain Symptom Manage. 2010;39(5):847-858.
26. Skerman HM, Yates PM, Battistutta D. Cancer-related symptom clusters for symptom management in outpatients after commencing adjuvant chemotherapy, at 6 months, and 12 months. Support Care Cancer. 2012; 20(1):95-105.
27. Jimenez A, Madero R, Alonso A, et al. Symptom clusters in advanced cancer. J Pain Symptom Manage. 2012;42(1):24-31.
28. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163-1169.
29. Serretti A, Benedetti F, Zanardi R, Smeraldi E. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):1074-1084.
30. Barton DA, Esler MD, Dawood T, et al. Elevated brain serotonin turnover in patients with depression: Effect of genotype and therapy. Arch Gen Psychiatry. 2008;65(1):38-46.
31. Neumeister A. Tryptophan depletion, serotonin, and depression: Where do we stand? Psychopharmacol Bull. 2003;37(4):99-115.
32. Neumeister A, Nugent AC, Waldeck T, et al. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry. 2004;61(8):765-773.
33. Cannon DM, Ichise M, Rollis D, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry. 2007;62(8):870-877.
34. Malison RT, Price LH, Berman R, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 betacarbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry. 1998;44(11):1090-1098.
35. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci. 2007;32(2): 86-102.
36. Nutt DJ. The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol. 2002;17(suppl 1):S1-S12.
37. Lambert G, Johansson M, Agren H, Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: Evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry. 2000;57(8):787-793.
38. Maes M, Van Gastel A, Delmeire L, Meltzer HY. Decreased platelet alpha-2 adrenoceptor density in major depression: Effects of tricyclic antidepressants and fluoxetine. Biol Psychiatry. 1999;45(3):278-284.
39. Young EA, Altemus M, Lopez JF, et al. HPA axis activation in major depression and response to fluoxetine: A pilot study. Psychoneuroendocrinology. 2004;29(9):1198-1204.
40. Contreras F, Menchon JM, Urretavizcaya M, Navarro MA, Vallejo J, Parker G. Hormonal differences between psychotic and non-psychotic melancholic depression. J Affect Disord. 2007;100(1-3):65-73.
41. Boyle MP, Brewer JA, Funatsu M, et al. Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Natl Acad Sci U S A. 2005;102(2):473-478.
42. Kling MA, Coleman VH, Schulkin J. Glucocorticoid inhibition in the treatment of depression: Can we think outside the endocrine hypothalamus? Depress Anxiety. 2009;26(7):641-649.
43. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5): 445-452.
44. Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: Clinical implications. J Clin Endocrinol Metab. 2005;90(5):2522-2530.
45. Dinan T, Siggins L, Scully P, O'Brien S, Ross P, Stanton C. Investigating the inflammatory phenotype of major depression: Focus on cytokines and polyunsaturated fatty acids. J Psychiatr Res. 2009;43(4):471-476.
46. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26(5): 643-652.
47. Yirmiya R, Pollak Y, Barak O, et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology. 2001;24(5):531-544.
48. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7(5):468-473.
49. O'Connor JC, Lawson MA, Andre C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009;14(5):511-522.
50. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: Relationship with proinflammatory cytokines and behavior. Mol Psychiatry. 2010;15(5):535-547.
51. Spath-Schwalbe E, Hansen K, Schmidt F, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab. 1998;83(5):1573-1579.
52. Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol. 1999;461:117-127.
53. Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry. 2003;160(1):64-75.
54. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386(6627):824-827.
55. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl). 2000; 152(4):383-389.
56. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a doubleblind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680-684.
57. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):201-217.
58. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary findings. Am J Psychiatry. 2001;158(8):1252-1257.
59. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl). 2003;170(4):429-433.
60. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(6):872-878.
61. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44(2):104-112.
62. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-741.
63. Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104(10):2222-2233.
64. Brown MS, Stemmer SM, Simon JH, et al. White matter disease induced by high-dose chemotherapy: Longitudinal study with MR imaging and proton spectroscopy. AJNR Am J Neuroradiol. 1998;19(2):217-221.
65. Swayampakula AK, Alkhouri N, Haut MW, Abraham J. Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer. Clin Adv Hematol Oncol. 2007;5(12):985-987; discussion 987-988.
66. Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clin Breast Cancer. 2006;7(1):67-78.
67. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87(11):5001-5007.
68. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: A prospective study. Psychooncology. 2009;18(8):811-821.
69. Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: A randomized controlled trial. BJU Int. 2002;90(4):427-432.
70. Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int. 2005;96(1):48-53.
71. Gizewski ER, Krause E, Wanke I, Forsting M, Senf W. Gender-specific cerebral activation during cognitive tasks using functional MRI: Comparison of women in mid-luteal phase and men. Neuroradiology. 2006;48(1): 14-20.
72. Hausmann M, Slabbekoorn D, Van Goozen SH, Cohen-Kettenis PT, Gunturkun O. Sex hormones affect spatial abilities during the menstrual cycle. Behav Neurosci. 2000;114(6):1245-1250.
73. SparkmanNL, Buchanan JB,Heyen JR, Chen J, Beverly JL, Johnson RW. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci. 2006;26(42):10709-10716.
74. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med. 2001;63(3):376-386.
75. Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): Results from a prospective study. Eur Psychiatry. 2006;21(3):204-210.
76. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788-793.
77. Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage. 2004;28(1):7-18.
78. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005;5(6):439-446.
79. Walker DJ, Zacny JP, Galva KE, Lichtor JL. Subjective, psychomotor, and physiological effects of cumulative doses of mixed-action opioids in healthy volunteers. Psychopharmacology (Berl). 2001;155(4):362-371.
80. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage. 1997;14(3):157-167.
81. Morita T, Tei Y, Tsunoda J, Inoue S, Chihara S. Increased plasma morphine metabolites in terminally ill cancer patients with delirium: An intraindividual comparison. J Pain Symptom Manage. 2002;23(2):107-113.
82. Konat GW, Kraszpulski M, James I, Zhang HT, Abraham J. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis. 2008;23(3):325-333.
83. Yuen HK, Sharma AK, Logan WC, Gillespie MB, Day TA, Brooks JO. Radiation dose, driving performance, and cognitive function in patients with head and neck cancer. Radiother Oncol. 2008;87(2):304-307.
84. Downie FP, Mar Fan HG, Houede-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: Evaluation with patient interview after formal assessment. Psychooncology. 2006;15(10):921-930.
85. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst. 2003;95(3):190-197.
86. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192-201.
87. Cunningham RS. Anemia in the oncology patient: Cognitive function and cancer. Cancer Nurs. 2003;26(suppl 6):38SY42S. 88. Bruera E,Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain. 1989;39(1):13-16.
88. Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. Am J Psychiatry. 1987;144(8):1062-1065.
89. Badawy AA, Morgan CJ, Llewelyn MB, Albuquerque SR, Farmer A. Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol. 2005;19(4):385-391.
90. Cleare AJ, Messa C, Rabiner EA, Grasby PM. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. Biol Psychiatry. 2005;57(3):239-246.
91. McGuire J, Ross GL, Price H, Mortensen N, Evans J, Castell LM. Biochemical markers for post-operative fatigue after major surgery. Brain Res Bull. 2003;60(1-2):125-130.
92. Soares DD, Coimbra CC, Marubayashi U. Tryptophan-induced central fatigue in exercising rats is related to serotonin content in preoptic area. Neurosci Lett. 2007;415(3):274-278.
93. Leite LH, Rodrigues AG, Soares DD, Marubayashi U, Coimbra CC. Central fatigue induced by losartan involves brain serotonin and dopamine content. Med Sci Sports Exerc. 2010;42(8):1469-1476.
94. Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev. 2003;24(2):236-252.
95. Lundstrom S, Furst CJ. Symptoms in advanced cancer: Relationship to endogenous cortisol levels. Palliat Med. 2003;17(6):503-508.
96. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4): 604-611.
97. Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med. 2005;67(2):277-280.
98. Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology. 2005;30(1):92-100.
99. Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer. 2002;10(4): 329-336.
100. Vollmer-Conna U, Fazou C, Cameron B, et al. Production of proinflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med. 2004;34(7):1289-1297.
101. Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW. Inflammatory responses to psychological stress in fatigued breast cancer survivors: Relationship to glucocorticoids. Brain Behav Immun. 2007;21(3): 251-258.
102. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12(9):2759-2766.
103. Gaab J, Rohleder N, Heitz V, et al. Stress-induced changes in LPSinduced pro-inflammatory cytokine production in chronic fatigue syndrome. Psychoneuroendocrinology. 2005;30(2):188-198.
104. Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006;24(12):1852-1859.
105. DiCarlo SE, Collins HL, Chen CY. Vagal afferents reflexly inhibit exercise in conscious rats. Med Sci Sports Exerc. 1994;26(4):459-462.
106. Pickar JG. The thromboxane A2 mimetic U-46619 inhibits somatomotor activity via a vagal reflex from the lung. Am J Physiol. 1998;275(3 pt 2): R706-R712.
107. Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanisms of cancer-related fatigue. Oncologist. 2007;12(suppl 1):22-34.
108. Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92(4): 321-328.
109. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999;82(2):185-191.
110. Castell LM, Yamamoto T, Phoenix J, Newsholme EA. The role of tryptophan in fatigue in different conditions of stress. Adv Exp Med Biol. 1999;467:697-704.
111. Bailey SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol. 1993;74(6):3006-3012.
112. Meeusen R, Watson P, Hasegawa H, Roelands B, Piacentini MF. Central fatigue: The serotonin hypothesis and beyond. Sports Med. 2006;36(10): 881-909.
113. Ek M, Kurosawa M, Lundeberg T, Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1beta: Role of endogenous prostaglandins. J Neurosci. 1998;18(22):9471-9479.
114. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1beta (IL-1beta) mRNA in the brain of rats in response to systemic IL-1beta. J Neurosci. 1998;18(6):2247-2253.
115. Mullington J, Korth C, Hermann DM, et al. Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol. 2000; 278(4):R947-R955.
116. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab. 1999; 84(8):2603-2607.
117. Vgontzas AN, Zoumakis M, Papanicolaou DA, et al. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism. 2002;51(7):887-892.
118. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82(5):1313- 1316.
119. Born J, Kern W, Bieber K, Fehm-Wolfsdorf G, Schiebe M, Fehm HL. Night-time plasma cortisol secretion is associated with specific sleep stages. Biol Psychiatry. 1986;21(14):1415-1424.
120. Follenius M, Brandenberger G, Bandesapt JJ, Libert JP, Ehrhart J. Nocturnal cortisol release in relation to sleep structure. Sleep. 1992;15(1): 21-27.
121. Buckley TM, Schatzberg AF. On the interactions of the hypothalamicpituitary-adrenal (HPA) axis and sleep: Normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab. 2005;90(5):3106-3114.
122. Rodenbeck A, Huether G, Ruther E, Hajak G. Interactions between evening and nocturnal cortisol secretion and sleep parameters in patients with severe chronic primary insomnia. Neurosci Lett. 2002;324(2):159-163.
123. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: Clinical implications. J Clin Endocrinol Metab. 2001;86(8):3787-3794.
124. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA. 1993;269(16):2110-2112.
125. Vgontzas AN, Bixler EO, Wittman AM, et al. Middle-aged men show higher sensitivity of sleep to the arousing effects of corticotropin-releasing hormone than young men: Clinical implications. J Clin Endocrinol Metab. 2001;86(4):1489-1495.
126. Buckley T, Duggal V, Schatzberg AF. The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: A pilot study. J Clin Sleep Med. 2008;4(3): 235-241.
127. Imeri L, De Simoni MG, Giglio R, Clavenna A, Mancia M. Changes in the serotonergic system during the sleep-wake cycle: Simultaneous polygraphic and voltammetric recordings in hypothalamus using a telemetry system. Neuroscience. 1994;58(2):353-358.
128. Portas CM, Bjorvatn B, Fagerland S, et al. On-line detection of extracellular levels of serotonin in dorsal raphe nucleus and frontal cortex over the sleep/wake cycle in the freely moving rat. Neuroscience. 1998;83(3):807-814.
129. Cespuglio R, Rousset C, Debilly G, Rochat C, Millan MJ. Acute administration of the novel serotonin and noradrenaline reuptake inhibitor, S33005, markedly modifies sleep-wake cycle architecture in the rat. Psychopharmacology (Berl). 2005;181(4):639-652.
130. Descamps A, Rousset C, Millan MJ, Spedding M, Delagrange P, Cespuglio R. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology (Berl). 2009;205(1):93-106.
131. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53(4):865-871.
132. Markov D, Goldman M. Normal sleep and circadian rhythms: Neurobiologic mechanisms underlying sleep and wakefulness. Psychiatr Clin North Am. 2006;29(4):841-853; abstract vii. 134. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113(2):296-320.
133. Monti JM, Jantos H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog Brain Res. 2008;172: 625-646.
134. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer. 2002;2(3):201-209.
135. Regan JM, Peng P. Neurophysiology of cancer pain. Cancer Control. 2000;7(2):111-119.
136. Delaney A, Fleetwood-Walker SM, Colvin LA, Fallon M. Translational medicine: Cancer pain mechanisms and management. Br J Anaesth. 2008; 101(1):87-94.
137. Peters CM, Ghilardi JR, Keyser CP, et al. Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol. 2005; 193(1):85-100.
138. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 2005;65(20):9426-9435.
139. Southall MD, Vasko MR. Prostaglandin E(2)Ymediated sensitization of rat sensory neurons is not altered by nerve growth factor. Neurosci Lett. 2000;287(1):33-36.
140. Ghilardi JR, Rohrich H, Lindsay TH, et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci. 2005; 25(12):3126-3131.
141. Martin CD, Jimenez-Andrade JM, Ghilardi JR, Mantyh PW. Organization of a unique net-like meshwork of CGRP+ sensory fibers in the mouse periosteum: Implications for the generation and maintenance of bone fracture pain. Neurosci Lett. 2007;427(3):148-152.
142. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999;19(24):10886-10897.
143. Cummins TR, Black JA, Dib-Hajj SD, Waxman SG. Glial-derived neurotrophic factor upregulates expression of functional SNS and NaN sodium channels and their currents in axotomized dorsal root ganglion neurons. J Neurosci. 2000;20(23):8754-8761.
144. Michaelis M, Vogel C, Blenk KH, Arnarson A, Janig W. Inflammatory mediators sensitize acutely axotomized nerve fibers to mechanical stimulation in the rat. J Neurosci. 1998;18(18):7581-7587.
145. Han HC, Lee DH, Chung JM. Characteristics of ectopic discharges in a rat neuropathic pain model. Pain. 2000;84(2-3):253-261.
146. Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci. 2002; 22(15):6724-6731.
147. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6(7):521-532.
148. Bielefeldt K, Christianson JA, Davis BM. Basic and clinical aspects of visceral sensation: Transmission in the CNS. Neurogastroenterol Motil. 2005; 17(4):488-499.
149. Cervero F, Laird JM. Visceral pain. Lancet. 1999;353(9170):2145-2148.
150. Al-Chaer ED, Feng Y, Willis WD. A role for the dorsal column in nociceptive visceral input into the thalamus of primates. J Neurophysiol. 1998;79(6):3143-3150.
151. Liu CN, Michaelis M, Amir R, Devor M. Spinal nerve injury enhances subthreshold membrane potential oscillations in DRG neurons: Relation to neuropathic pain. J Neurophysiol. 2000;84(1):205-215.
152. Wu G, Ringkamp M, Hartke TV, et al. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J Neurosci. 2001;21(8):RC140.
153. Uceyler N, Rogausch JP, Toyka KV, Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology. 2007;69(1): 42-49.
154. Schafers M, Sommer C. Anticytokine therapy in neuropathic pain management. Expert Rev Neurother. 2007;7(11):1613-1627.
155. Nagamine K, Ozaki N, Shinoda M, et al. Mechanical allodynia and thermal hyperalgesia induced by experimental squamous cell carcinoma of the lower gingiva in rats. J Pain. 2006;7(9):659-670.
156. Maier SF, Wiertelak EP, Martin D, Watkins LR. Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res. 1993;623(2):321-324.
157. Schaible HG, Richter F. Pathophysiology of pain. Langenbecks Arch Surg. 2004;389(4):237-243.
158. Urch CE, Donovan-Rodriguez T, Dickenson AH. Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain. 2003; 106(3):347-356.
159. Kerr BJ, Bradbury EJ, Bennett DL, et al. Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci. 1999;19(12):5138-5148.
160. Donovan-Rodriguez T, Urch CE, Dickenson AH. Evidence of a role for descending serotonergic facilitation in a rat model of cancer-induced bone pain. Neurosci Lett. 2006;393(2-3):237-242.
161. Suzuki R, Rahman W, Hunt SP, Dickenson AH. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res. 2004;1019(1-2): 68-76.
162. Vasquez E, Bar KJ, Ebersberger A, Klein B, Vanegas H, Schaible HG. Spinal prostaglandins are involved in the development but not the maintenance of inflammation-induced spinal hyperexcitability. J Neurosci. 2001;21(22):9001- 9008.
163. Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain. 2000;4(3):247-257.
164. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: Distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci. 2008;28(20):5189-5194.
165. Zhou HY, Chen SR, Chen H, Pan HL. Opioid-induced long-term potentiation in the spinal cord is a presynaptic event. J Neurosci. 2010; 30(12):4460-4466.
166. Rivat C, Laboureyras E, Laulin JP, Le Roy C, Richebe P, Simonnet G. Non-nociceptive environmental stress induces hyperalgesia, not analgesia, in pain and opioid-experienced rats. Neuropsychopharmacology. 2007;32(10): 2217-2228.
167. Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage. 2000;20(3):214-232.
168. Miller AH. Cytokines and sickness behavior: Implications for cancer care and control. Brain Behav Immun. 2003;17(suppl 1):S132-S134.
169. Dantzer R. Cytokine-induced sickness behavior: Mechanisms and implications. Ann N Y Acad Sci. 2001;933:222-234.
170. Bluthe RM, Laye S, Michaud B, Combe C, Dantzer R, Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharideinduced sickness behaviour: A study with interleukin-1 type I receptorY deficient mice. Eur J Neurosci. 2000;12(12):4447-4456.
171. Bluthe RM, Michaud B, Poli V, Dantzer R. Role of IL-6 in cytokineinduced sickness behavior: A study with IL-6 deficient mice. Physiol Behav. 2000;70(3-4):367-373.
172. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis. J Surg Oncol. 2003; 84(3):151-159.
173. Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and highrisk myelodysplastic syndromes. Cancer. 2008;113(7):1605-1613.
174. Sasaki A, Ishiuchi S, Kanda T, Hasegawa M, Nakazato Y. Analysis of interleukin-6 gene expression in primary human gliomas, glioblastoma xenografts, and glioblastoma cell lines. Brain Tumor Pathol. 2001;18(1):13-21.
175. Elsea CR, Roberts DA, Druker BJ, Wood LJ. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS One. 2008; 3(6):e2355.
176. Muller K, Meineke V. Radiation-induced alterations in cytokine production by skin cells. Exp Hematol. 2007;35(4 suppl 1):96-104.
177. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25(3):94-102.
178. QuanN, BanksWA. Brain-immune communication pathways. Brain Behav Immun. 2007;21(6):727-735.
179. Quan N, Whiteside M, Herkenham M. Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience. 1998;83(1):281-293.
180. Verma S, Nakaoke R, Dohgu S, Banks WA. Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav Immun. 2006;20(5):449-455.
181. Hansen MK, O'Connor KA, Goehler LE, Watkins LR, Maier SF. The contribution of the vagus nerve in interleukin-1betaYinduced fever is dependent on dose. Am J Physiol Regul Integr Comp Physiol. 2001;280(4): R929-R934.
182. Burks TF. New agents for the treatment of cancer-related fatigue. Cancer. 2001;92(suppl 6):1714-1718.
183. Miaskowski C, Cooper BA, Paul SM, et al. Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: A cluster analysis. Oncol Nurs Forum. 2006;33(5):E79-E89.
184. Pud D, Ben Ami S, Cooper BA, et al. The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes. J Pain Symptom Manage. 2008;35(2):162-170.
185. Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. Oncol Nurs Forum. 2000;27(9):1443-1448.
186. Miaskowski C, Paul SM, Cooper BA, et al. Trajectories of fatigue in men with prostate cancer before, during, and after radiation therapy. J Pain Symptom Manage. 2008;35(6):632-643.
187. Gemma C, Imeri L, de Simoni MG, Mancia M. Interleukin-1 induces changes in sleep, brain temperature, and serotonergic metabolism. Am J Physiol. 1997;272(2 pt 2):R601-R606.
188. Romanovsky AA, Kulchitsky VA, Akulich NV, et al. First and second phases of biphasic fever: Two sequential stages of the sickness syndrome? Am J Physiol. 1996;271(1 pt 2):R244-R253.
189. Romanovsky AA, Simons CT, Kulchitsky VA. ''Biphasic'' fevers often consist of more than two phases. Am J Physiol. 1998;275(1 pt 2):R323-R331.
190. Nestler EJ, Hyman SE, Malenka RC. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. New York: McGraw-Hill; 2001.
191. Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry. 2004;49(2):139-144.
192. Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006;15(3): 259-267.
193. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: A randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003;21(24):4635-4641.
194. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005;89(3):243-249.
195. Barkin RL, Fawcett J. The management challenges of chronic pain: The role of antidepressants. Am J Ther. 2000;7(1):31-47.
196. Sindrup SH, Brosen K, Gram LF. The mechanism of action of antidepressants in pain treatment: Controlled cross-over studies in diabetic neuropathy. Clin Neuropharmacol. 1992;15(suppl 1 pt A):380AY381A. 199. Davis MP, Khawam E, Pozuelo L, Lagman R. Management of symptoms associated with advanced cancer: Olanzapine and mirtazapine. A World Health Organization project. Expert Rev Anticancer Ther. 2002; 2(4):365-376.
197. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002; 23(5):442-447.
198. Castanon N, Bluthe RM, Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl). 2001;154(1):50-60.
199. Dunn AJ, Swiergiel AH. The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment. Neuroimmunomodulation. 2001;9(3):163-169.
200. Merali Z, Brennan K, Brau P, Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1beta: Antidepressant and gender effects on responding for ''free chow'' and ''earned'' sucrose intake. Psychopharmacology (Berl). 2003;165(4):413-418.
201. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci. 1999;65(17): 1773-1786.
202. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961-966.
203. Capuron L, Dantzer R. Cytokines and depression: The need for a new paradigm. Brain Behav Immun. 2003;17(suppl 1):S119-S124.
204. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alphaY induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54(9):906-914.
205. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry. 2003;160(7):1342-1345.
206. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. J Clin Oncol. 2003;21(23):4439-4443.
207. Challman TD, Lipsky JJ. Methylphenidate: Its pharmacology and uses. Mayo Clin Proc. 2000;75(7):711-721.
208. Rozans M, Dreisbach A, Lertora JJ, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: A review. J Clin Oncol. 2002;20(1): 335-339.
209. Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald RN. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep. 1987;71(1):67-70.
210. Bruera E, Fainsinger R, MacEachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain. 1992;50(1):75-77.
211. Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer. 1995;3(2):135-138.
212. Dalal S, Melzack R. Potentiation of opioid analgesia by psychostimulant drugs: A review. J Pain Symptom Manage. 1998;16(4):245-253.
213. Dalal S, Melzack R. Psychostimulant drugs potentiate morphine analgesia in the formalin test. J Pain Symptom Manage. 1998;16(4):230-239.
214. Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992;48(2):163-166.
215. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522-2527.
216. Fernandez F, Adams F. Methylphenidate treatment of patients with head and neck cancer. Head Neck Surg. 1986;8(4):296-300.
217. Homsi J, Walsh D, Nelson KA, LeGrand S, Davis M. Methylphenidate for depression in hospice practice: A case series. Am J Hosp Palliat Care. 2000;17(6):393-398.
218. Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care. 2001;18(6):403-407.
219. Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage. 1998;16(3):193-198.
220. Hanna A, Sledge G, Mayer ML, et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer. 2006;14(3):210-215.
221. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: A pilot study of exercise and methylphenidate. Oncol Nurs Forum. 2002;29(7):E85-E90.
222. Sugawara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: A preliminary study. Palliat Med. 2002;16(3):261-263.
223. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med. 2001;161(3):411-420.
224. Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial. Mov Disord. 2007;22(14):2070-2076.
225. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosisassociated fatigue. Chest. 2008;133(5):1189-1195.
226. Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, doubleblind, placebo-controlled study of long-acting methylphenidate for cancerrelated fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673-3679.
227. Mar Fan HG, Clemons M, Xu W, et al. A randomised, placebocontrolled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer. 2008;16(6):577-583.
228. Butler JM Jr, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d- threomethylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496-1501.
229. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: A double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006;24(13):2073-2078.
230. Merali Z, Lacosta S, Anisman H. Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: A regional microdialysis study. Brain Res. 1997;761(2):225-235.
231. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferontreated epithelial cells. Cytokine. 2000;12(6):588-594.
232. Guillemin GJ, Kerr SJ, Pemberton LA, et al. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: Potential implications for multiple sclerosis treatment. J Interferon Cytokine Res. 2001;21(12): 1097-1101.
233. Lestage J, Verrier D, Palin K, Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun. 2002;16(5):596-601.
234. Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res. 2003;23(8):413-421.
235. McEwen BS, Biron CA, Brunson KW, et al. The role of adrenocorticoids as modulators of immune function in health and disease: Neural, endocrine and immune interactions. Brain Res Brain Res Rev. 1997;23(1-2):79-133.
236. Dunn AJ, Vickers SL. Neurochemical and neuroendocrine responses to Newcastle disease virus administration in mice. Brain Res. 1994;645(1-2): 103-112.
237. Guo AL, Petraglia F, Criscuolo M, et al. Adrenergic and serotoninergic receptors mediate the immunological activation of corticosterone secretion in male rats. Gynecol Endocrinol. 1996;10(3):149-154.
238. Jorgensen H, Knigge U, Kjaer A, Moller M, Warberg J. Serotonergic stimulation of corticotropin-releasing hormone and pro-opiomelanocortin gene expression. J Neuroendocrinol. 2002;14(10):788-795.
239. Jorgensen HS. Studies on the neuroendocrine role of serotonin. Dan Med Bull. 2007;54(4):266-288.
240. Wang XS, Shi Q, Williams LA, et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008;113(8):2102-2109.
241. McEwen BS. Clinical review 108: The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab. 1999;84(6):1790-1797.
242. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev. 2003;24(2):133-151.
243. Berendsen HH. The role of serotonin in hot flushes. Maturitas. 2000; 36(3):155-164.
244. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer. 2007;110(7):1629-1640.
245. Payne J, Piper B, Rabinowitz I, Zimmerman B. Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: A pilot study. Oncol Nurs Forum. 2006;33(4):775-783.
246. Parker KP, Kimble LP, Dunbar SB, Clark PC. Symptom interactions as mechanisms underlying symptom pairs and clusters. J Nurs Scholarsh. 2005;37(3):209-215.